What is the focus of lymphoma research in 2017?
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
The issue of relapse in Philadelphia chromosome-positive ALL patients and how to combat this
Developing targeted therapies to combine with venetoclax in acute myeloid leukemia (AML)
Targeted treatments for AML: the revolution